Acquired resistance to PD-L1 inhibition can rewire the interferon-regulated secretory machinery in tumor cells, altering the ...

The TIME is a dynamic network composed of cancer cells, immune cells, and stromal components. During the early stages of tumorigenesis, the TIME ...

BNT327, now in early-phase trials, is part of a class of drugs that could one day challenge Keytruda’s dominance. BioNTech ...

The keys to the lock are immune checkpoints such as programmed cell-death ligand 1 (PD-L1), and its receptor PD-1; discovering this system earned Nobel Prizes for James Allison, at the University ...

There is growing evidence that immune-positron emission tomography (immuno-PET) can provide a real-time quantitative readout ...

The European Commission’s decision is based on two Phase III trials where Tevimbra plus chemotherapy improved overall ...

This study will focus on the treatment of newly diagnosed locally advanced primary head and neck cancer patients with no lymph node involvement and low (TPS <10) PD-L1 tumor expression.

Tiragolumab is a novel immune checkpoint inhibitor that binds to TIGIT, a protein receptor on immune cells, which suppresses ...

A multinational collaboration co-led by the Garvan Institute of Medical Research has uncovered a potential explanation for why some cancer patients receiving a type of immunotherapy called checkpoint ...

The addition of tiragolumab to Tecentriq in patients with advanced PD-L1-high NSCLC failed to improve overall survival in a Phase III trial.